209 related articles for article (PubMed ID: 21862953)
1. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study.
Flaxel C; Schain MB; Hamon SC; Francis PJ
Retina; 2012 Mar; 32(3):417-23. PubMed ID: 21862953
[TBL] [Abstract][Full Text] [Related]
2. A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration.
Russo A; Costagliola C; Delcassi L; Romano MR; Semeraro F
Br J Ophthalmol; 2013 Oct; 97(10):1273-6. PubMed ID: 23873901
[TBL] [Abstract][Full Text] [Related]
3. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
Gomi F; Sawa M; Tsujikawa M; Nishida K
Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
[TBL] [Abstract][Full Text] [Related]
4. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration.
Zweifel SA; Engelbert M; Khan S; Freund KB
Retina; 2009; 29(10):1527-31. PubMed ID: 19898185
[TBL] [Abstract][Full Text] [Related]
5. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
[TBL] [Abstract][Full Text] [Related]
7. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.
Singer MA; Awh CC; Sadda S; Freeman WR; Antoszyk AN; Wong P; Tuomi L
Ophthalmology; 2012 Jun; 119(6):1175-83. PubMed ID: 22306121
[TBL] [Abstract][Full Text] [Related]
8. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration.
Ranchod TM; Ray SK; Daniels SA; Leong CJ; Ting TD; Verne AZ
Retina; 2013 Sep; 33(8):1600-4. PubMed ID: 23549100
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
10. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
Zweifel SA; Saroj N; Shapiro H; Freund KB
Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
[TBL] [Abstract][Full Text] [Related]
11. 16-Gy low-voltage x-ray irradiation with ranibizumab therapy for AMD: 6-month safety and functional outcomes.
Canton VM; Quiroz-Mercado H; Velez-Montoya R; Lopez-Miranda MJ; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Ophthalmic Surg Lasers Imaging; 2011; 42(6):468-73. PubMed ID: 21830747
[TBL] [Abstract][Full Text] [Related]
12. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
13. One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.
Arias L; Roman I; Masuet-Aumatell C; Rubio MJ; Caminal JM; Catala J; Pujol O
Retina; 2011; 31(7):1261-7. PubMed ID: 21499194
[TBL] [Abstract][Full Text] [Related]
14. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
16. 16 and 24 Gy low-voltage X-ray irradiation with ranibizumab therapy for neovascular age-related macular degeneration: 12-month outcomes.
Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Moshfeghi AA; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Am J Ophthalmol; 2013 Jun; 155(6):1000-1008.e2. PubMed ID: 23497847
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2.
Abraham P; Yue H; Wilson L
Am J Ophthalmol; 2010 Sep; 150(3):315-324.e1. PubMed ID: 20598667
[TBL] [Abstract][Full Text] [Related]
18. 16 Gy low-voltage x-ray irradiation followed by as needed ranibizumab therapy for age-related macular degeneration: 12 month outcomes of a 'radiation-first' strategy.
Moshfeghi AA; Morales-Canton V; Quiroz-Mercado H; Velez-Montoya R; Zavala-Ayala A; Shusterman EM; Kaiser PK; Sanislo SR; Gertner M; Moshfeghi DM
Br J Ophthalmol; 2012 Oct; 96(10):1320-4. PubMed ID: 22895887
[TBL] [Abstract][Full Text] [Related]
19. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Rosenfeld PJ; Heier JS; Hantsbarger G; Shams N
Ophthalmology; 2006 Apr; 113(4):623.e1. PubMed ID: 16581423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
